If small molecules immunotherapy comes, can the prime be far behind?
文献类型：期刊论文
| 作者 | Zhang, Jingyu2; Zhang, Yu2; Qu, Bingxue2; Yang, Haiyan3,4; Hu, Shengquan2; Dong, Xiaowu1,2,5 |
| 刊名 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2021-06-05 |
| 卷号 | 218 |
| ISSN号 | 0223-5234 |
| 关键词 | Cancer immunotherapy Small molecule inhibitors Combination therapy Tumor microenvironment |
| DOI | 10.1016/j.ejmech.2021.113356 |
| 通讯作者 | Hu, Shengquan(18210083083@163.com) ; Dong, Xiaowu(dongxw@zju.edu.cn) |
| 英文摘要 | Anti-cancer immunotherapy, which includes cellular immunotherapy, immune checkpoint inhibitors and cancer vaccines, has transformed the treatment strategies of several malignancies in the past decades. Immune checkpoints blockade (ICB) is the most commonly tested therapy and has the potential to induce a durable immune response in different types of cancers. However, all approved immune checkpoint inhibitors (ICIs) are monoclonal antibodies (mAbs), which are fraught with disadvantages including lack of oral bioavailability, prolonged tissue retention and poor membrane permeability. Therefore, the research focus has shifted to developing small molecule inhibitors to obviate the limitations of mAbs. Given the complexity of the tumor micro-environment (TME), the combination of ICIs with various small molecule agonists/inhibitors are currently being tested in clinical trials to improve treatment outcomes and prevent tumor recurrence. In this review, we have summarized the mechanisms and therapeutic potential of several molecular targets, along with the current status of small molecule inhibitors. (c) 2021 Elsevier Masson SAS. All rights reserved. |
| WOS关键词 | BRUTONS TYROSINE KINASE ; CHRONIC LYMPHOCYTIC-LEUKEMIA ; TUMOR-MICROENVIRONMENT ; CHECKPOINT BLOCKADE ; SUPPRESSOR-CELLS ; NEXT-GENERATION ; TOLL-LIKE ; T-CELLS ; SODIUM STIBOGLUCONATE ; ADENOSINE RECEPTORS |
| 资助项目 | Key R&D Program of Zhejiang Province, National Natural Science Foundation of China |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
| WOS记录号 | WOS:000646195900005 |
| 资助机构 | Key R&D Program of Zhejiang Province, National Natural Science Foundation of China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/122191]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Hu, Shengquan; Dong, Xiaowu |
| 作者单位 | 1.Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China 2.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Hangzhou 310058, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Beijing, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Beijing, Peoples R China 5.Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310058, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Jingyu,Zhang, Yu,Qu, Bingxue,et al. If small molecules immunotherapy comes, can the prime be far behind?[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2021,218. |
| APA | Zhang, Jingyu,Zhang, Yu,Qu, Bingxue,Yang, Haiyan,Hu, Shengquan,&Dong, Xiaowu.(2021).If small molecules immunotherapy comes, can the prime be far behind?.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,218. |
| MLA | Zhang, Jingyu,et al."If small molecules immunotherapy comes, can the prime be far behind?".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 218(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。